Creative Medical Technology Holdings (CELZ) Non-Current Debt (2016 - 2017)
Creative Medical Technology Holdings' (CELZ) quarterly Non-Current Debt came in at $25000.0 in Q1 2017, up 37.36% year-over-year from $18200.0 in Q1 2016, and little changed quarter-over-quarter from $25000.0 in Q4 2016.
Powered by 
Analysis
Creative Medical Technology Holdings (CELZ) Non-Current Debt (2016 - 2017) Analysis & Trends
Creative Medical Technology Holdings (CELZ) has reported Non-Current Debt for 2 consecutive years, with $25000.0 the latest figure, recorded in Q1 2017.
- On a quarterly basis, Non-Current Debt rose 37.36% year-over-year to $25000.0 in Q1 2017; TTM through Mar 2017 was $25000.0, a 37.36% increase from a year earlier, with the FY2016 full-year figure at $25000.0, changed N/A from the prior year.
- Non-Current Debt was $25000.0 for Q1 2017 at Creative Medical Technology Holdings, roughly flat from $25000.0 in the prior quarter.
- Over five years, Non-Current Debt peaked at $69031.0 in Q2 2016 and troughed at $18200.0 in Q1 2016.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Krystal Biotech | 10.60 Bn | 9.76 Bn | 112.79 Mn | - |
| 2 | CRISPR Therapeutics AG | 5.39 Bn | 5.39 Bn | - | 586.20 Mn |
| 3 | Iovance Biotherapeutics | 3.98 Bn | 3.68 Bn | 55.72 Mn | - |
| 4 | Legend Biotech | 3.97 Bn | 3.00 Bn | 251.50 Mn | - |
| 5 | uniQure | 3.09 Bn | 3.09 Bn | 5.49 Mn | 50.15 Mn |
| 6 | Beam Therapeutics | 3.06 Bn | 3.06 Bn | - | 100.26 Mn |
| 7 | Precigen | 2.54 Bn | 2.54 Bn | 52.17 Mn | 93.88 Mn |
| 8 | Sarepta Therapeutics | 2.38 Bn | 1.58 Bn | 251.87 Mn | 847.62 Mn |
| 9 | Vericel | 2.06 Bn | 1.89 Bn | 56.40 Mn | - |
| 10 | Creative Medical Technology Holdings | 1.48 Mn | 1.50 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2017 | 25,000.00 |
| Dec 31, 2016 | 25,000.00 |
| Sep 30, 2016 | 25,000.00 |
| Jun 30, 2016 | 69,031.00 |
| Mar 31, 2016 | 18,200.00 |